Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia

NCT03771664 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03771664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03771664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
February 4, 2019
Completion date
January 17, 2020
Enrollment
87 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia, major depressive disorder